- Investing Ideas
- Polish Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Polish Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
2
0 new
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
2 companies
Selvita
Market Cap: zł543.3m
Provides drug discovery, drug development, and contract testing services in Poland.
SLV
zł28.30
7D
-7.2%
1Y
-11.0%
Ryvu Therapeutics
Market Cap: zł344.5m
A clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally.
RVU
zł14.58
7D
-8.9%
1Y
-53.1%